Barclays lowered the firm’s price target on Relay Therapeutics to $14 from $15 and keeps an Overweight rating on the shares. The analyst updated the company’s model following termination of the SHP2 inhibitor collaboration with Roche. The firm continues to see an attractive risk/reward ahead of Q4 PI3K data update in breast cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics price target lowered to $21 from $24 at JMP Securities
- 3 Best Stocks to Buy Now, 7/18/2024, According to Top Analysts
- Relay Therapeutics price target lowered to $18 from $20 at H.C. Wainwright
- AI Could Revolutionize Drug Discovery: A Look at Key Players
- Relay Therapeutics to explore RLY-2608 outside of cancer, says Oppenheimer
Questions or Comments about the article? Write to editor@tipranks.com